ImmunoPrecise Antibodies Ltd. (IPA)

NASDAQ: IPA · IEX Real-Time Price · USD
1.520
-0.050 (-3.18%)
Mar 28, 2024, 4:00 PM EDT - Market closed

Company Description

ImmunoPrecise Antibodies Ltd., together with its subsidiaries, operates as a biotherapeutic research and technology company in Canada and internationally.

It provides NonaVac DNA for complex protein classes, including GPCRs and ion channels; and Rapid Prime, a positive monoclonal antibodies for generating anti-idiotypic antibodies, and producing monoclonal antibodies against conformational epitopes.

The company also offers syngeneic cell line for immunization and screening; and peptide production for subsequent antibody discovery campaign.

In addition, it provides B cell select platform which allows for the interrogation of animal antibody repertoire; screening of the immune repertoire of rabbits and chickens and select the desired antibody directly from the B cells; single step hybridoma, a semi-solid media to grow mouse and rat hybridomas; and DeepDisplay, a combination of transgenic animal platform and custom IPA phage display antibody selection.

The company also offers phage display, a custom immune libraries from multiple species; and CAR development, an adaptable antibody which allows the inclusion of functional data early in the screening funnel.

Further, it provides silico developability, a profiling toolset for antibody lead candidates; and vitro analytical tools for the study of various critical quality attributes.

Additionally, the company offers LucinaTech, an antibody humanization to identify essential framework and CDR residues; antibody affinity maturation for therapeutic and diagnostic application; and antibody chimerization for cloning and production of variable antibody domain.

It also provides Eurofins preclinical services; hybrid service model, a service model designed to reduce time and risk with custom technologies and applications; and breadth and depth to accelerate assay development, screening cascades, drug candidate validation, and new biotherapeutic concepts.

The company was incorporated in 1983 and is headquartered in Victoria, Canada.

ImmunoPrecise Antibodies Ltd.
ImmunoPrecise Antibodies logo
Country Canada
Founded 1983
IPO Date Jan 3, 2017
Industry Biotechnology
Sector Healthcare
Employees 102
CEO Dr. Jennifer Lynne Bath Ph.D.

Contact Details

Address:
880 - 580 Hornby Street
Vancouver, A1 V6C3B6
British Columbia, Canada
Phone 6048060626
Website ipatherapeutics.com

Stock Details

Ticker Symbol IPA
Exchange NASDAQ
Fiscal Year May - April
Reporting Currency USD
CIK Code 0001715925
CUSIP Number 45257F200
ISIN Number CA45257F2008
SIC Code 2834

Key Executives

Name Position
Dr. Jennifer Lynne Bath Ph.D. Chief Executive Officer, President and Non-Independent Director
Dr. Ilse Roodink Chief Scientific Officer and Interim General Manager of IPA Europe, Oss
Kristin Taylor CPA, M.B.A. Chief Financial Officer
David E. Orton Chief Operating Officer
Dr. Roland Romijn Head of General Operations of the Utrecht site of IPA (Europe)

Latest SEC Filings

Date Type Title
Mar 28, 2024 6-K Report of foreign issuer
Mar 20, 2024 6-K Report of foreign issuer
Mar 14, 2024 6-K Report of foreign issuer
Mar 14, 2024 6-K Report of foreign issuer
Mar 7, 2024 6-K Report of foreign issuer
Feb 27, 2024 SC 13G Statement of acquisition of beneficial ownership by individuals
Feb 23, 2024 6-K Report of foreign issuer
Feb 23, 2024 424B5 Filing
Feb 15, 2024 6-K/A Filing
Jan 10, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals